• <noscript id="yywya"><kbd id="yywya"></kbd></noscript>
  • 發布時間:2019-08-03 00:03 原文鏈接: RNAiprotocol

     

    siRNA protocols

    Our current strategy with siRNA is to synthesis relatively small amounts enzymatically and use these to test for efficiency by western blotting. This allows us to test several candidate siRNAs quite cheaply. The yields are good enough for reasonable amounts of experimental work, but for larger use we get successful siRNAs synthesised chemically by Dharmacon.


    Design

    The Tuschl lab siRNA users guide gives information about how to choose the basic target sequence. For enzymatic synthesis, the target sequences for the preparation of T7 polymerase transcribed siRNA are of the form G(N17)C. The first and last nucleotide constraints are required because T7 polymerase puts a G at the start of all transcripts. RNAs are synthesised from templates that are double stranded in the region of the T7 promoter and single stranded in the region encoding the RNA of interest. Such templates are generated by annealing a 20-mer T7 promoter primer oligonucleotide to a 40-mer target oligonucleotide, one for the sense strand and one for the antisense strand. Transcription from these templates will generate complementary RNAs. Once annealed, the siRNA will be double stranded for 19 nt with 2 NT 3' overhangs, always UU in the sense strand RNA.


    siRNA synthesis

    i. Annealing template

    For this you need to prepare two reactions: one for the sense oligo and one for the antisense oligo. Dissolve oligo at 100 uM in water and combine oligo with T7 promoter oligo at 5 uM each in 90 mM Tris pH8.0. 

    90ul 90mM Tris, pH 8.0
    5ul oligo
    5ul T7 promoter oligo (5'-GGTAATACGACTCACTATAG-3')

    Heat at 95oC for 3min.
    Snap cool on ice.

    ii. Small scale transcription reaction

    Set up two reactions. One with the sense template and one with the antisense template.

    40ul water
    5ul 10x T7 Buffer*
    2ul 25mM NTPs (1mM final)
    1ul annealed template mix (100nM final)
    2ul T7 RNA polymerase (50U/ul)

    Incubate at 37oC for 2h.
    Add 1ul (1U/ul) DNase I (RNase Free)
    Incubate at 37oC for 15min


    *10x T7 buffer: 0.4M Tris pH 8, 60mM MgCl2, 50mM DTT, 10mM spermidine, 0.1% Triton X-100, 500ug/ml BSA. Prepare without BSA, filter through 0.2um filter, add BSA, correct volume.

    iii. Generate siRNA duplexes

    Combine sense and antisense transcription reactions.
    Heat at 95oC for 5min.
    Incubate at 37oC for 1h.
    Precipitate by adding 6.7ul 3M sodium acetate pH 5.2 + 250ul ethanol.

    (Note that there is no need to chill precipitations as there is plenty of RNA and chilling can cause precipitation of undesirables)

    Centrifuge in benchtop microfuge at room temperature for 5min.
    Wash once with 70% ethanol
    Air dry
    Dissolve in 50ul water.

    Transfection

    i. Oligofectamine

    We have used Oligofectamine transfection successfully with a range of mammalian cultured cells. The protocol is that derived and optimised by the Tuschl lab and can be found in the very useful siRNA users guide.

    ii. Calcium phosphate

    Day 1 Plate HeLa cells at 75000 cells/ml in DMEM with 10% FCS.
    Day 2 Transfect in late afternoon/evening. Mix siRNA with filter-sterilised 0.25 M CaCl2 then with filter-sterilised BBS (50 mm BES, pH 6.95, 280 mm NaCl, 1.5 mm Na2HPO4). Leave 15-20 min then add dropwise to plates whilst swirling. Remove plate to a 3% CO2 incubator.

    For a 10cm plate with 10 ml medium, use 500ul CaCl2, 500ul BBS and 10ul siRNA.

    Day 3 Wash plate once with PBS then add fresh medium and return to 5% CO2 incubator for 1 hour. Wash once more with PBS and replace with fresh medium again.
    Day 4 Harvest.

    Oligofectamine works very well but is also very expensive. We have had seemingly identical results using calcium phosphate, at least in HeLa cells. This has the obvious advantage of being much cheaper.


     

    General notes

    In our hands, the yield of siRNA from the small scale synthesis is 0.5-2.5ug. This provides sufficient reagent to transfect 5-10cm plates or 25 wells of 6-well dishes. The reaction should scale up with no loss of yield.

    The RNAs can be visualised on a 4% agarose gel. We recommend using low melting temperature agarose and loading samples without sample buffer into dry wells. Run the gel for 5-10 min with sufficient running buffer to generate a current through the gel without covering the top. Once the samples have entered the gel, cover the gel with buffer and continue the run. Sample buffer in a separate lane should be used to assess progress of the run.

    All reagents are purchased as molecular biology grade and RNase free. Fingertips and equipment used for DNA preparations involving RNase are the most likely sources of contaminating RNase. The best way of ensuring an RNase free environment is to use plasticware, including tips, that have never been touched by human hands. Autoclaving is probably not a very effective method of removing RNase. Change gloves regularly to protect against cross contamination.


    References

    The above procedure is based upon published methods from:

    1. Milligan,J.F. and Uhlenbeck,O.C. (1989) Synthesis of small RNAs using T7 RNA polymerase. Methods Enzymol., 180, 51-62.
    2. Elbashir,S.M., Harborth,J., Lendeckel,W., Yalcin,A., Weber,K. an Tuschl,T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
    3. Donze,O. and Picard,D. (2002) RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res., 30, e46.
    4. Chen,C.A. and Okayama,H. (1988) Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques, 6, 632-638.


    相關文章

    利用跨界RNAi提高生防真菌殺蟲效力的新方法

    10月25日,中國科學院分子植物科學卓越創新中心研究員王四寶團隊等在CellReports上,在線發表了題為ExpressionofmosquitomiRNAsinentomopathogenicfu......

    武漢病毒所在昆蟲RNAi抗病毒免疫研究中獲進展

    中國科學院武漢病毒研究所/病毒學國家重點實驗室研究員周溪團隊在昆蟲RNAi抗病毒免疫研究方面取得重要進展,揭示依諾沙星(Enoxacin)通過增強昆蟲體內的RNAi抗病毒免疫,對多種病毒顯示出廣譜抗病......

    靶向病毒RNAi抑制子的抗病毒藥物研發新策略

    RNAi是一種在真核生物中高度保守的轉錄后基因沉默機制,同時也是一種高效的抗病毒天然免疫機制。當病毒感染宿主細胞后,病毒RNA復制所產生的dsRNA被RNAi通路關鍵蛋白Dicer識別,并切割成病毒來......

    7億美元開發,RNAi治療痛風新模式

    2021年6月21日,ArrowheadPharmaceuticals與HorizonTherapeutics聯合宣布,兩家公司就在研RNA干擾(RNAi)療法ARO-XDH達成全球合作和許可協議,用......

    RNAi是合成殺蟲劑的高效替代品

    (圖片來源于網絡,如有侵權,請聯系刪除)基于RNAi的藥物是合成殺蟲劑的高效替代品。RNA干擾(RNAinterference,RNAi)是由RNA分子引發的特異性阻礙靶標基因表達的自然生物過程,普遍......

    治療罕見肝病!AROAATII期研究完成首例患者給藥!

    Arrowhead是一家臨床階段的生物技術公司,致力于利用RNA干擾(RNAi)抑制致病基因的轉錄后表達,開發治療難治性疾病的創新藥物。近日,該公司宣布,評估RNAi藥物ARO-AAT的II期研究AR......

    皮下RNAi療法AROAATII期研究完成首例患者給藥!

    Arrowhead是一家臨床階段的生物技術公司,致力于利用RNA干擾(RNAi)抑制致病基因的轉錄后表達,開發治療難治性疾病的創新藥物。近日,該公司宣布,評估RNAi藥物ARO-AAT的II期研究AR......

    全球第二款RNAi藥物!創新藥Givlaari獲FDA批準,可治療AHP

    Alnylam制藥公司是RNAi療法開發領域的領軍企業,該公司藥物Onpattro(patisiran)于2018年8月獲美國和歐盟批準,用于遺傳性ATTR(hATTR)淀粉樣變性成人患者第1階段或第......

    PCSK9靶向RNAi藥物inclisiranIII期研究成功,顯著降低LDLC

    TheMedicinesCompany(TMC)公司近日在費城舉行的2019年美國心臟協會(AHA)年度科學會議上公布了siRNA降脂藥物inclisiranIII期臨床研究ORION-10的詳細數據......

    PCSK9靶向RNAi藥物inclisiranIII期項目成功,顯著降低LDLC!

    TheMedicinesCompany(TMC)公司近日公布siRNA降脂藥物inclisiran兩項III期臨床研究(ORION-9,ORION-10)的積極頂線數據。ORION-9研究在雜合子家族......

  • <noscript id="yywya"><kbd id="yywya"></kbd></noscript>
  • 东京热 下载